3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Influenza, Human
13
Neoplasms
6
Colorectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Recurrence
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Virus Diseases
1
Vaccine-Preventable Diseases
1
Vaccination Hesitancy
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Patient Acceptance of Health Care
1
Ovarian Neoplasms
1
Osteosarcoma
1
Interventions
Cyclophosphamide
8
dinutuximab
7
Magnetic Resonance Spectroscopy
7
Topotecan
6
Doxorubicin
6
sargramostim
5
Vincristine
5
Stem Cell Transplantation
5
Radiation
5
Platinum
5
Melphalan
5
Isotretinoin
5
Colony-Stimulating Factors
5
Cisplatin
5
Biopsy
5
1,2-diaminocyclohexaneplatinum II citrate
5
Temozolomide
4
Specimen Handling
4
Irinotecan
4
Etoposide
4
Congresses as Topic
4
Carboplatin
4
Thiotepa
3
Busulfan
3
3-Iodobenzylguanidine
3
etoposide phosphate
2
Razoxane
2
Dexrazoxane
2
temsirolimus
1
lorlatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ganglioneuroblastoma
×
Influenza Vaccines
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled